(Q51045200)

27 March 2018

title

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (English)

1 reference

27 March 2018

author name string

Bob Djavan

1

1 reference

27 March 2018

Juliana Laze

2

1 reference

27 March 2018

Elisabeth Eckersberger

3

1 reference

27 March 2018

Julia Finkelstein

4

1 reference

27 March 2018

Ilir Agalliu

5

1 reference

27 March 2018

Herbert Lepor

6

1 reference

27 March 2018

publication date

28 March 2011

1 reference

27 March 2018

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

BJU International

1 reference

27 March 2018

volume

108

1 reference

27 March 2018

issue

10

1 reference

27 March 2018

page(s)

1582-1587

1 reference

27 March 2018

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Time to return to work and physical activity following open radical retropubic prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10173.X

10.1111/J.1464-410X.2011.10173.X

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018